Year: 2023

LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, will host a conference call on Tuesday, November 7, 2023 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2023. The Company’s results will be reported in a press release prior to the call. Dave management will host the conference call, followed by a question-and-answer period. The conference call details are as follows: Date: Tuesday, November 7, 2023Time: 4:30 p.m. Eastern timeDial-in registration link: hereLive webcast registration link: here The conference call will also be available for replay in the Events section of the Company’s website, along with the transcript, at https://investors.dave.com. If you have any difficulty registering for...

DALLAS, TX, Oct. 24, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Auri Inc. (OTC PINK: AURI) (“AURI”) (the “Company”) is proud to announce “Knockout” Champ Line, featuring legendary boxer and two-time world champion Riddick Bowe. The full product line will be nationally distributed to stores. The champ “Knockout” includes a full line of products featuring Delta9 and CBD as key ingredients in specially designed gummies and drinks. The company and management team are excited that the first products will hit stores in the Texas area as soon as next week. Further nationwide distribution will take place rapidly. www.aurinetwork.com CEO Mr. Jim Amendola states, “We are excited to be releasing the ‘Champ’ line in a rapid pace to stores. Our company isn’t just selling online but also is actively placing the...

Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome (NS). This study, which is being conducted under Quoin’s open Investigational New Drug (IND) application, is an open-label, single-arm trial that is evaluating 10 NS patients dosed with QRX003 over a twelve week period. All subjects in the study are continuing to receive off-label systemic therapy for the duration...

The Company’s designated Notified Body confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that the full CE Mark approval process of obtaining clearance of sales in the European Union for the LIBERTY® Robotic Surgical System, will be carried out in parallel with the FDA regulatory process BRAINTREE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces it has received confirmation for the commencement of the process to support its future CE Mark approval, and to ultimately allow the Company to market the LIBERTY® Robotic Surgical System in Europe as well as other regions who accept the CE Mark. According to the confirmation, the...

Company Announcement, Helsinki, 24 October 2023 at 3 PM (EEST) Nexstim Plc: Composition of the Shareholders’ Nomination Committee Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces the composition of the Shareholders’ Nomination Committee. Leena Niemistö, Chair of the Board of Nexstim and representative of the Company’s largest shareholder, continues to chair the Nomination Committee. Ossi Haapaniemi, and Kyösti Kakkonen as a representative of Joensuun Kauppa ja Kone Oy continue as members of the committee. According to the document establishing Nexstim’s Nomination Committee, it must have three to four members. The three largest shareholders of the Company each nominate one member; if a shareholder does not exercise the right to nominate a representative, the right is passed on to the next largest shareholder. The...

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve University, in an oral presentation titled, “SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against a Broad-spectrum of Fungal Pathogens, and Dose-dependent Tissue Distribution In Vivo” at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens Greece October 20-23, 2023. “We are excited to see the progress...

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional DyspepsiaFIGURE 1Primary Endpoint (n=35): Average number of nausea pills. Overall significance (Type 3 F test): p=0.0007ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23-25, 2023 regarding the potential for nVNS to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis (GP) or Functional Dyspepsia (FD). Many gastrointestinal disorders can cause nausea and vomiting,...

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick...

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma BASKING RIDGE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial by Dr. Ian Hu, a principal investigator of the study, at The University of Texas MD Anderson Cancer Center in Houston, Texas. The Company had previously announced the...